Peihua Lu, MD, discusses CD7-targeted CAR-T cell therapy at ASH 2024
Anti-CD7 CAR-T therapy for T-ALL/LBLПодробнее
Late Complications and Long-term Care of CAR T-cell Patients | Michael Bishop | #ASH24Подробнее
CAR T Cells in Multiple MyelomaПодробнее
A Look at How CAR-T Cell Therapy WorksПодробнее
CD-7 targeted CAR-T therapy in heavily pretreated patients with AML: a Phase I trialПодробнее
CAR-T and cellular therapy at ASH 2020Подробнее
Evaluating the safety and efficacy of novel anti-CD7 universal CAR-T therapy in R/R T-ALL and T-LBLПодробнее
ASH 2024: Wael Gamal, PhD on PI3K Inhibition to Enhance CAR T-Cell Therapy in CLLПодробнее
Novel CAR T-cell therapies for hematological malignancies: exploring new targetsПодробнее
Sattva Neelapu, MD, shares his approach to optimizing CAR T-Cell therapiesПодробнее
CAR T-cell therapy treating myelomaПодробнее
A Look at How CAR-T Cell Therapy WorksПодробнее
PD-1 & PDL-1 combinations with CAR T-cell therapyПодробнее
Phase I trial of donor-derived CD7 CAR T-cells for T-ALLПодробнее
How CAR T-Cell Therapy Has Evolved in Hematologic MalignanciesПодробнее
CD79b-specific CAR T-cell therapy: overcoming treatment resistance in B-cell lymphomaПодробнее
Updates in CAR T Cell TherapiesПодробнее
CAR T-Cell TherapyПодробнее
